# Octant

> Octant is an Emeryville clinical-stage biotechnology company developing small molecule correctors for protein misfolding diseases. Its Navigator platform combines barcoded human cell assays, high-throughput chemistry and computation; its lead candidate OCT-980 entered patient testing for RHO-associated retinitis pigmentosa in September 2026.

- **Founded:** 2017
- **Headquarters:** Emeryville, United States
- **Founders:** Sri Kosuri (Cofounder and CEO), Ramsey Homsany (Cofounder and President)
- **Products:** OCT-980, The Octant Navigator, Deep mutational scanning collaborations
- **Notable:** First healthy volunteer dosed with OCT-980 in March 2026., First patient with RHO-adRP dosed in September 2026., Published a cross-validated functional map measuring trafficking of all 6,612 possible RHO missense variants in July 2026.

## Products & services

- **OCT-980** — Investigational oral small molecule corrector for RHO-associated autosomal dominant retinitis pigmentosa; Phase 1b/2 patient dosing began September 2026.
- **The Octant Navigator** — Internal discovery platform combining engineered cellular reporters, deep mutational scanning, high-throughput synthesis and machine learning.
- **Deep mutational scanning collaborations** — Research partnerships that map how protein variants behave and respond to compounds.

## Achievements

- First healthy volunteer dosed with OCT-980 in March 2026.
- First patient with RHO-adRP dosed in September 2026.
- Published a cross-validated functional map measuring trafficking of all 6,612 possible RHO missense variants in July 2026.
- Reported screening 250,000 molecular analogs during its rhodopsin corrector campaign.

## Latest updates

- **2026-09** — First patient dosed in the Phase 1b/2 OCT-980 study for RHO-associated retinitis pigmentosa.
- **2026-07** — Published a comprehensive rhodopsin missense trafficking map covering 6,612 variants.
- **2026-04** — Partnered with Foundation Fighting Blindness to add an RHO cohort to Uni-Rare.
- **2026-03** — First healthy volunteer dosed with OCT-980.
- **2025-11** — Signed a neurodegeneration research and license agreement with Bristol Myers Squibb.

## Links

- Website: https://www.octant.bio/
- LinkedIn: https://www.linkedin.com/company/octantbio
- Twitter/X: https://x.com/OctantBio
- GitHub: https://github.com/octantbio

---

Profile page: https://yespress.io/octant
Published by YesPress — https://yespress.io
Last updated: 2026-09-29